1 – 5 of 7
- show: 5
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
A “patient-industry complex”? Investigating the financial dependency of UK patient organisations on drug company funding
(
- Contribution to journal › Article
-
Mark
Tip of the iceberg? Country- and company-level analysis of drug company payments for research and development in Europe
(
- Contribution to journal › Article
- 2021
-
Mark
Failure of responsive regulation? : Pharmaceutical marketing, corporate impression management and off-label promotion of enzalutamide in Europe
(
- Contribution to journal › Article
- 2020
-
Mark
The will of Congress? Permissive regulation and the strategic use of labeling for the anti-influenza drug Relenza
(
- Contribution to journal › Article
- 2019
-
Mark
Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK
(
- Contribution to journal › Article